Summary
This is a study that is evaluating how safe and tolerable a drug called YL242 is when given by itself and in combination with other treatments in people with advanced solid cancers.
The study has multiple parts.
Part 1 and Part 2
In this part, YL242 will be evaluated by itself (monotherapy). Participants will receive YL242 as an intravenous infusion (IV). People with advanced, unresectable or metastatic solid cancers who have received at least one prior line of systemic anti-cancer therapy.
Part 3 and 4
This part will evaluate a combination dose of YL242 in combination with pembrolizumab immunotherapy. Part 3 will enrol the same people as Parts 1 and 2, while Part 4 will enrol people with locally advanced or metastatic non-squamous non-small cell lung cancer without AGA and HCC, who have not received any systemic anti-cancer treatment.
Part 5
In this part, participants will receive YL242 in combination with chemotherapy - 5FU and LV. This part will enrol people with metastatic colorectal cancer who have received at least one (5a) or one (5b) prior line of systemic anti-tumour treatment.
Part 6
In this part, participants will receive YL242 with pembrolizumab immunotherapy and 5-FU chemotherapy. This part will enrol people with advanced or metastatic HER-negative gastric or gastro-oesophageal junction cancer who have received at least one (6a) or one (6b) prior line of systemic anti-cancer therapy.
Conditions
This trial is treating people with advanced, metastatic or unresectable solid cancers, including non-small cell lung cancer, colorectal cancer, stomach cancer or gastro-oesophageal junction cancer